Adma Biologics, Inc. Announces Resignation of Eric I. Richman as Board of Director and Any Committees of the Board
April 03, 2020 at 05:03 pm
Share
On March 30, 2020, Eric I. Richman notified ADMA Biologics, Inc. that he has decided to resign, effective as of March 31, 2020, as a member of the company's Board of Directors and any committees of the Board in order to pursue other opportunities.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.